

Non-binding translation of summary

DISCLAIMER

This non-binding summary is not a translation of the offer document published by SPARTA AG on September 1, 2020 and does not constitute an offer to the shareholders of 4basebio AG. This non-binding summary should only provide an overview to the shareholders of 4basebio AG in English language and does not have any legal effects.

All information about the takeover bid by SPARTA AG to the shareholders of 4basebio AG is contained exclusively in the offer document published on September 1, 2020 and available in German language only.

By publishing the offer document, the bidder is not making a public offer under any law other than that of Germany (particularly that of the USA).

The publication of the offer document was only permitted by the Federal Financial Supervisory Authority ("BaFin"). As a result, no announcements, registrations, admissions or approvals of the offer document and / or the offer outside Germany have been applied for, initiated or granted.

SPARTA AG shall not be liable or bear any responsibility for the accuracy, integrity, actuality or ongoing availability of the information provided in this non-binding summary and does not undertake to update it.

Furthermore, SPARTA AG accepts no liability on contractual or legal grounds (including negligence), nor for any other reason, for losses or damages, including lost profit or any other direct or consequential damages, arising from the use of, or reliance on the information provided in the this non-binding summary. This applies accordingly to any non-consideration of certain information.

Non-binding translation of summary

Mandatory publication
pursuant to § 34, § 14 (2) and (3) of the German Securities Acquisition and Takeover Act
(WpÜG)

Shareholders of 4basebio AG, especially those with residence, registered office or habitual abode outside the Federal Republic of Germany, should pay particular attention to the information contained in sections 1 and 18 of this offer document.

OFFER DOCUMENT

Voluntary public takeover bid of

SPARTA AG

Ziegelhäuser Landstraße 1, 69120 Heidelberg, Germany
(local court Hamburg, HRB 58870)

to the shareholders of

4basebio AG

Waldhofer Strasse 102, 69123 Heidelberg
(local court Mannheim, HRB 335706)

for the acquisition of all registered shares against
payment of a cash consideration of 2.00 euros per share of
4basebio AG

Acceptance period:

**1 September 2020 to 29 September 2020, 24:00 hours (local time Frankfurt am
Main)**

Shares of 4basebio AG: ISIN: DE000A2YN801
4basebio shares tendered for sale: ISIN: DE000A289WC9

Non-binding translation of summary

SUMMARY OF THE TAKEOVER BID

Bidder:	SPARTA AG with its registered office in Hamburg, Germany (AG Hamburg, HRB 58870), business address: Ziegelhäuser Landstraße 1, 69120 Heidelberg, Germany
Target Company:	4basebio AG with its registered office in Heidelberg, Germany (AG Mannheim, HRB 335706), business address: Waldhofer Strasse 102, 69123 Heidelberg, Germany
Subject of the Offer:	<p>Acquisition of all no-par value registered shares of the Bidder not directly held by the Bidder of 4basebio AG (ISIN: DE000A2YN801 / WKN: A2YN80) including all ancillary rights associated with it at the time of the settlement of the takeover bid.</p> <p>The offer relates only to 4basebio shares. Other securities relating to 4basebio shares are expressly not subject of this takeover bid.</p>
Offer consideration:	2.00 euros per 4basebio share (" Consideration ")
Acceptance Period:	1 September 2020 to 29 September 2020, 24:00 (local time Frankfurt am Main)
Additional Acceptance Period:	The Additional Acceptance Period (as defined in section 4.6) is expected to start on 7 October 2020 and end on 20 October 2020, 24:00 (local time Frankfurt am Main).

Non-binding translation of summary

Acceptance during the Acceptance Period and during the Additional Acceptance Period:	<p>The acceptance of this Offer has to be declared in relation to the custodian institutions within the Acceptance Period (as defined in section 4.3) respective within the Additional Acceptance Period (as defined in section 4.6) and in accordance with the formalities pursuant to the instructions of the custodian institutions for their instructions. The acceptance shall become effective with the timely transfer of the tendered 4basebio shares within the Acceptance Period (as defined in section 4.3) or the Additional Acceptance Period (as defined in section 4.6) into ISIN DE000A289WC9 with Clearstream Banking AG, Frankfurt am Main, Germany (“Clearstream”).</p> <p>The transfer is deemed to be timely if it is effected at the latest by 18:00 (local time Frankfurt am Main) on the second Banking Day following end of the Acceptance Period (as defined in section 4.3) respective the Additional Acceptance Period (as defined section 4.6).</p>
Costs of acceptance:	<p>The Bidder will not assume any taxes, fees or domestic or foreign costs or expenses incurred by custodian institutions in connection with the acceptance of this Offer. 4basebio shareholders who wish to accept the Offer are recommended to obtain advice from their Custodian Institution with regard to any taxes, costs, fees and expenses that may arise before acceptance.</p>

Non-binding translation of summary

Conditions of enforcement:	<p>The takeover bid and the contracts resulting from its acceptance will only be implemented if the following three conditions are met:</p> <ul style="list-style-type: none">(i) from the publication of the offer document until the expiry of the acceptance period, no conversion or option rights are issued by the Target Company from which conversion rights or option rights of new shares of the Target Company during the Acceptance Period can be exercised.(ii) from the publication of the offer document until the expiry of the Acceptance Period, the Target Company will not take any decision on the use of its authorised capital.(iii) from the publication of the offer document until the expiry of the Acceptance Period, no general meeting of the Target Company decides on a dividend. <p>The conditions of enforcement are resolutive conditions.</p>
Stock Exchange Trading:	4basebio shares tendered for sale (as described in section 4.1) cannot be traded on a stock exchange.
ISIN:	<p>Shares of 4basebio AG:</p> <p>ISIN DE000A2YN801</p> <p>4basebio shares tendered for sale (as defined in section 4.1):</p> <p>ISIN DE000A289WC9</p>

Non-binding translation of summary

Publications:	<p>The Offer Document, which publication was permitted by BaFin on 31 August 2020, will be published on 1 September 2020 by way of announcement on the internet at https://sparta.de/spv2/investoren/4basebio/ and by making free copies available at the Bidder at the business address SPARTA AG, Ziegelhäuser Landstraße 1, 69120 Heidelberg, Germany, Telefax: +49 6221 6492424. The announcement that this offer document is available free of charge and the Internet address at which the offer document is published will be published on 1 September 2020 in the Federal Gazette (<i>Bundesanzeiger</i>).</p> <p>All publications and notices required under the WpÜG in connection with this Offer will be made in German language on the internet at https://sparta.de/spv2/investoren/4basebio/ and in the Federal Gazette (<i>Bundesanzeiger</i>).</p>
----------------------	---

Non-binding translation of summary

Settlement:	<p>The consideration will be paid to the 4basebio shareholder accepting the offer after expiry of the Acceptance Period for the 4basebio shares tendered for sale within the Acceptance Period to the account of the custodian institution of the respective 4basebio shareholder accepting the offer concurrently with the transfer of the 4basebio shares tendered for sale.</p> <p>4basebio shares will be credited to the account of Bankhaus Gebr. Martin AG with Clearstream, acting on behalf of the Central Settlement Agent for the 4basebio shares tendered for sale during the Additional Acceptance Period (as defined in section 4.6), the consideration will be credited to the account of the custodian institution of the respective 4basebio shareholder accepting the Offer after expiry of the Additional Acceptance Period, also concurrently with the transfer of the tendered for Sale 4basebio shares credited.</p> <p>The relevant custodian institution will credit the consideration due to the 4basebio shareholder accepting the offer to his/her account.</p> <p>Settlement will take place at the earliest on the third and at the latest on the eighth Banking Day following the expiry of the Acceptance Period or the Additional Acceptance Period.</p>
Taxation:	<p>The Bidder recommends that every 4basebio shareholder should consider his/her personal circumstances before deciding on this Offer.</p>

Central Settlement Agent

mwb fairtrade Wertpapierhandelsbank AG, Rottenbucher Strasse 28, 82166 Graefelfing, Germany, fax: +49 89 85852 505, will support the settlement of the offer process as the central settlement agent. Internet address: info@mwbfairtrade.com